(ALXO) Alx Oncology Holdings - Ratings and Ratios
Therapeutic, Biologics, Cancer, Immuno-Oncology, Combination
ALXO EPS (Earnings per Share)
ALXO Revenue
Description: ALXO Alx Oncology Holdings
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company that is aggressively pursuing innovative cancer therapies in the United States. The companys lead product candidate, Evorpacept, is a CD47 blocking therapeutic biologic being developed as a combination therapy with other anti-cancer agents. Evorpacept has shown promise in various clinical trials, including Phase 2 studies for Gastric/GEJ cancer and head and neck squamous cell carcinoma, as well as Phase 1 studies for urothelial cancer.
The companys strategic collaborations with prominent pharmaceutical companies and research institutions, such as Jazz Pharmaceuticals, Quantum Leap Healthcare, MD Anderson Cancer Center, Sanofi, and University of Pittsburgh, underscore its commitment to advancing Evorpacept and other potential therapies. These partnerships are focused on exploring Evorpacepts potential in combination with various anti-cancer agents, including zanidatamab, fam-trastuzumab deruxtecan-nxki, rituximab, lenalidomide, isatuximab, and pembrolizumab, across a range of cancer types.
In addition to Evorpacept, ALX Oncology is also developing ALTA-002, a potent immune activator targeted to myeloid cells in the tumor, through its collaboration with Tallac Therapeutics, Inc. The companys robust pipeline and collaborations are supported by its license agreements with prestigious institutions, including the Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc.
From a technical analysis perspective, ALXOs stock price has been trending downward, with a current price of $0.48, below its 50-day and 200-day moving averages. The Average True Range (ATR) of 0.05 indicates a relatively low volatility, but the stock is still trading near its 52-week low of $0.41. Given the companys promising pipeline and collaborations, a potential catalyst for growth could be successful trial results or regulatory approvals. If Evorpacept demonstrates efficacy in its ongoing trials, we could see a significant increase in the stock price, potentially targeting the $1.00-$2.00 range in the short term, representing a 100%-300% increase from current levels.
Fundamentally, ALX Oncologys market capitalization is approximately $23.05 million, with no P/E ratio due to the companys current lack of profitability. The companys return on equity is negative, reflecting its significant investment in research and development. However, if Evorpacept or other pipeline candidates demonstrate success, the companys valuation could increase substantially. Based on the current data, a forecast for ALXOs stock price would depend on the outcome of its ongoing clinical trials and the success of its collaborations. If the trials yield positive results, we could see a significant upward revision in the stock price, potentially driven by increased investor confidence and a revaluation of the companys potential.
ALXO Stock Overview
| Market Cap in USD | 59m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-07-17 |
ALXO Stock Ratings
| Growth Rating | -87.4% |
| Fundamental | 45.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -58.9% |
| Analyst Rating | 4.33 of 5 |
ALXO Dividends
Currently no dividends paidALXO Growth Ratios
| Growth Correlation 3m | 90.3% |
| Growth Correlation 12m | -76.7% |
| Growth Correlation 5y | -88.2% |
| CAGR 5y | -56.02% |
| CAGR/Max DD 3y | -0.57 |
| CAGR/Mean DD 3y | -0.97 |
| Sharpe Ratio 12m | -1.50 |
| Alpha | -69.44 |
| Beta | 0.838 |
| Volatility | 126.69% |
| Current Volume | 411.4k |
| Average Volume 20d | 560k |
| Stop Loss | 0.9 (-15.1%) |
| Signal | -1.57 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-116.6m TTM) > 0 and > 6% of Revenue (6% = 52.1k TTM) |
| FCFTA -1.28 (>2.0%) and ΔFCFTA -67.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7651 % (prev 5253 %; Δ 2398 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -1.11 (>3.0%) and CFO -105.5m > Net Income -116.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (53.4m) change vs 12m ago 3.11% (target <= -2.0% for YES) |
| Gross Margin 27.88% (prev 65.73%; Δ -37.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.56% (prev 1.16%; Δ -0.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -68.99 (EBITDA TTM -115.3m / Interest Expense TTM 1.68m) >= 6 (WARN >= 3) |
Altman Z'' -46.68
| (A) 0.70 = (Total Current Assets 85.3m - Total Current Liabilities 18.8m) / Total Assets 95.3m |
| (B) -7.11 = Retained Earnings (Balance) -677.8m / Total Assets 95.3m |
| warn (B) unusual magnitude: -7.11 — check mapping/units |
| (C) -0.75 = EBIT TTM -116.2m / Avg Total Assets 155.0m |
| (D) -21.93 = Book Value of Equity -677.7m / Total Liabilities 30.9m |
| Total Rating: -46.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 45.04
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.19 = 2.48 |
| 5. Debt/Ebitda -0.10 = -2.50 |
| 7. RoE -115.7% = -2.50 |
| 8. Rev. Trend 9.61% = 0.48 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 63.17% = 1.58 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ALXO shares?
Over the past week, the price has changed by -4.50%, over one month by +61.83%, over three months by +99.40% and over the past year by -51.38%.
Is Alx Oncology Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALXO is around 0.63 USD . This means that ALXO is currently overvalued and has a potential downside of -40.57%.
Is ALXO a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALXO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.3 | 112.3% |
| Analysts Target Price | 2.3 | 112.3% |
| ValueRay Target Price | 0.7 | -34% |
Last update: 2025-09-10 04:31
ALXO Fundamental Data Overview
CCE Cash And Equivalents = 79.3m USD (Cash And Short Term Investments, last quarter)
P/S = 5906.2383
P/B = 0.927
Beta = 1.116
Revenue TTM = 868.0k USD
EBIT TTM = -116.2m USD
EBITDA TTM = -115.3m USD
Long Term Debt = 7.00m USD (from longTermDebt, last quarter)
Short Term Debt = 5.05m USD (from shortTermDebt, last quarter)
Debt = 12.0m USD (Calculated: Short Term 5.05m + Long Term 7.00m)
Net Debt = -16.3m USD (from netDebt column, last quarter)
Enterprise Value = -7.83m USD (59.4m + Debt 12.0m - CCE 79.3m)
Interest Coverage Ratio = -68.99 (Ebit TTM -116.2m / Interest Expense TTM 1.68m)
FCF Yield = -1564 % (FCF TTM -122.4m / Enterprise Value -7.83m)
FCF Margin = -14.1k% (FCF TTM -122.4m / Revenue TTM 868.0k)
Net Margin = -13.4k% (Net Income TTM -116.6m / Revenue TTM 868.0k)
Gross Margin = 27.88% ((Revenue TTM 868.0k - Cost of Revenue TTM 626.0k) / Revenue TTM)
Tobins Q-Ratio = 0.01 (Enterprise Value -7.83m / Book Value Of Equity -677.7m)
Interest Expense / Debt = 3.36% (Interest Expense 405.0k / Debt 12.0m)
Taxrate = 21.0% (US default)
NOPAT = -116.2m (EBIT -116.2m, no tax applied on loss)
Current Ratio = 4.52 (Total Current Assets 85.3m / Total Current Liabilities 18.8m)
Debt / Equity = 0.19 (Debt 12.0m / last Quarter total Stockholder Equity 64.4m)
Debt / EBITDA = -0.10 (Net Debt -16.3m / EBITDA -115.3m)
Debt / FCF = -0.10 (Debt 12.0m / FCF TTM -122.4m)
Total Stockholder Equity = 100.8m (last 4 quarters mean)
RoA = -122.3% (set to none)
RoE = -115.7% (Net Income TTM -116.6m / Total Stockholder Equity 100.8m)
RoCE = -107.8% (set to none) (Ebit -116.2m / (Equity 100.8m + L.T.Debt 7.00m))
RoIC = -104.9% (set to none) (NOPAT -116.2m / Invested Capital 110.7m)
WACC = 8.01% (E(59.4m)/V(71.5m) * Re(9.10%)) + (D(12.0m)/V(71.5m) * Rd(3.36%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.50%
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -122.4m)
Revenue Correlation: 9.61 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -1185
EPS Correlation: 63.17 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 46.83
Additional Sources for ALXO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle